The Blue Box key facts
as of Oct 2026- Developer of a breast cancer detection device designed to detect early signs of late-stage breast cancer at home.
- The Blue Box is valued at approximately $10.4M as of Oct 2026 (last reported valuation).
- It has raised $5.5M; the latest was Early Stage VC ($3.5M) in Jul 2025.
- Notable investors include MassChallenge, Berkeley SkyDeck, 4YFN, CancerX (USA), Unconventional Ventures — 23 tracked in total.
- Status: Privately Held (backing).
The Blue Box's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 23 names
- ·Watch The Blue Box: the Monday email on marks, rounds and moves
The Blue Box funding rounds
No funding rounds for The Blue Box are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs The Blue Box
23+Membership and data by Private Market View
The Blue Box valuation
The Blue Box's last reported valuation was $10.4 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
The Blue Box investors
23 investors are on record for The Blue Box, including MassChallenge, Berkeley SkyDeck, 4YFN and CancerX (USA).
About The Blue Box
Developer of a breast cancer detection device designed to detect early signs of late-stage breast cancer at home. The company's device uses a urine sample and an artificial intelligence algorithm and contains chemical sensors that are specifically sensitive to some breast cancer biomarkers, enabling women to test for breast cancer at home.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2021
- Employees
- 10
- Website
- thebluebox.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.